European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Concept paper on the development of a reflection paper on proof-of-concept data to support the development of anti-cancer medicinal products in paediatric patients

Submitted by Anonymous (not verified) on 13 March 2026 - 7:00

Concept paper on the development of a reflection paper on proof-of-concept data to support the development of anti-cancer medicinal products in paediatric patients

Human medicines European public assessment report (EPAR): Elucirem, gadopiclenol, Date of authorisation: 07/12/2023, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 12 March 2026 - 16:48

Human medicines European public assessment report (EPAR): Elucirem, gadopiclenol, Date of authorisation: 07/12/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Vueway, gadopiclenol, Date of authorisation: 07/12/2023, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 12 March 2026 - 16:46

Human medicines European public assessment report (EPAR): Vueway, gadopiclenol, Date of authorisation: 07/12/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Tecartus, brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 17, Status: Authorised

Submitted by Anonymous (not verified) on 12 March 2026 - 16:44

Human medicines European public assessment report (EPAR): Tecartus, brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Yescarta, axicabtagene ciloleucel, Date of authorisation: 23/08/2018, Revision: 22, Status: Authorised

Submitted by Anonymous (not verified) on 12 March 2026 - 16:38

Human medicines European public assessment report (EPAR): Yescarta, axicabtagene ciloleucel, Date of authorisation: 23/08/2018, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Forxiga, dapagliflozin, Date of authorisation: 11/11/2012, Revision: 33, Status: Authorised

Submitted by Anonymous (not verified) on 12 March 2026 - 16:32

Human medicines European public assessment report (EPAR): Forxiga, dapagliflozin, Date of authorisation: 11/11/2012, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), lenalidomide, Date of authorisation: 11/02/2021, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 12 March 2026 - 16:20

Human medicines European public assessment report (EPAR): Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), lenalidomide, Date of authorisation: 11/02/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Quviviq, daridorexant, Date of authorisation: 29/04/2022, Revision: 11, Status: Authorised

Submitted by Anonymous (not verified) on 12 March 2026 - 16:14

Human medicines European public assessment report (EPAR): Quviviq, daridorexant, Date of authorisation: 29/04/2022, Revision: 11, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness